Relapsed/Refractory T- Acute Lymphoblastic Leukemia - Current Options and Future Directions
© 2023. The Author(s), under exclusive licence to Dr. K C Chaudhuri Foundation..
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. The T-cell subtype (T-ALL) accounts for 10-15% of pediatric ALL cases and has been historically associated with outcomes inferior to those of B-cell ALL (B-ALL). The prognosis of T-ALL has significantly improved with contemporary intensive pediatric regimens. However, most children with relapsed T-ALL have dismal outcomes and fewer therapeutic salvage options than those available for B-ALL. After demonstrating efficacy in relapsed T-ALL, nelarabine is being increasingly incorporated into frontline T-ALL regimens. The development of genomic sequencing has led to the identification of new T-ALL subgroups and potential targeted therapeutic approaches which could improve patients' outcomes and reduce the toxicity associated with current therapy. Immunotherapy and cellular therapy regimens are also under early investigation in T-cell malignancies. This review outlines the clinical and biological characteristics of T-ALL and provides an overview of novel treatment options for refractory and relapsed T-ALL.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:91 |
|---|---|
| Enthalten in: |
Indian journal of pediatrics - 91(2024), 2 vom: 29. Jan., Seite 168-175 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jeha, Sima [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Childhood leukemia |
|---|
| Anmerkungen: |
Date Completed 18.01.2024 Date Revised 18.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12098-023-04745-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361408676 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361408676 | ||
| 003 | DE-627 | ||
| 005 | 20240118231907.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12098-023-04745-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1263.xml |
| 035 | |a (DE-627)NLM361408676 | ||
| 035 | |a (NLM)37642889 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jeha, Sima |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Relapsed/Refractory T- Acute Lymphoblastic Leukemia - Current Options and Future Directions |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.01.2024 | ||
| 500 | |a Date Revised 18.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Dr. K C Chaudhuri Foundation. | ||
| 520 | |a Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. The T-cell subtype (T-ALL) accounts for 10-15% of pediatric ALL cases and has been historically associated with outcomes inferior to those of B-cell ALL (B-ALL). The prognosis of T-ALL has significantly improved with contemporary intensive pediatric regimens. However, most children with relapsed T-ALL have dismal outcomes and fewer therapeutic salvage options than those available for B-ALL. After demonstrating efficacy in relapsed T-ALL, nelarabine is being increasingly incorporated into frontline T-ALL regimens. The development of genomic sequencing has led to the identification of new T-ALL subgroups and potential targeted therapeutic approaches which could improve patients' outcomes and reduce the toxicity associated with current therapy. Immunotherapy and cellular therapy regimens are also under early investigation in T-cell malignancies. This review outlines the clinical and biological characteristics of T-ALL and provides an overview of novel treatment options for refractory and relapsed T-ALL | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Childhood leukemia | |
| 650 | 4 | |a New agents | |
| 650 | 4 | |a T-cell malignancies | |
| 773 | 0 | 8 | |i Enthalten in |t Indian journal of pediatrics |d 1945 |g 91(2024), 2 vom: 29. Jan., Seite 168-175 |w (DE-627)NLM000070742 |x 0973-7693 |7 nnns |
| 773 | 1 | 8 | |g volume:91 |g year:2024 |g number:2 |g day:29 |g month:01 |g pages:168-175 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12098-023-04745-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 91 |j 2024 |e 2 |b 29 |c 01 |h 168-175 | ||